United Health Products (UEEC) Q4 2024 earnings summary

Executive summary

• Focused on developing and commercializing CelluSTAT®, a patented hemostatic gauze, with efforts centered on obtaining FDA Class III and CE Mark approvals for surgical use; commercial activities paused pending regulatory outcomes.

• Submitted full FDA PMA application in March 2024; FDA requested additional data, pausing review until further information is provided; supplemental clinical study planned.

• Considering strategic alternatives including sale, merger, or commercial partnerships with industry leaders; several companies have expressed interest.

Financial highlights

• No revenue generated in 2024 or 2023 due to focus on regulatory approval.

• Net loss for 2024 was $2,001,733, an improvement from $2,623,267 in 2023, primarily due to lower operating expenses and a gain on debt settlement.

• Operating expenses decreased to $2,007,572 in 2024 from $2,426,539 in 2023, driven by lower litigation, legal, and R&D costs, partially offset by higher stock compensation and inventory write-down.

• Cash on hand at year-end 2024 was $168,883, up from $95,420 in 2023.

Outlook and guidance

• Business strategy depends on successful FDA and CE Mark approvals; if not obtained, a significant strategic shift will be required.

• Plans to pursue commercial partnerships, licensing, or a sale/merger if approvals are granted; no assurance of success.

• Additional financing will be needed to fund operations and execute the business plan; future financings may be dilutive.